Blood Science Update|China Expert Consensus on mNGS for Diagnosing Infections in Hematological Disorders (2024) 

Blood Science Update|China Expert Consensus on mNGS for Diagnosing Infections in Hematological Disorders (2024) 

The 2024 China Expert Consensus on metagenomic next-generation sequencing (mNGS) in hematological disorders, published in Blood Science, offers the first national guidance on how mNGS should be applied to infection diagnosis in this highly vulnerable population. Because hematological diseases and their treatments cause profound immunosuppression, infections remain a major cause of morbidity and mortality. Traditional microbiological tests (CMTs) frequently produce delayed or negative results, especially after antibiotic exposure. mNGS, which enables broad, unbiased pathogen detection, has therefore become an essential complementary tool. 
Blood Science Update|A Prognostic Analysis of Acute Leukemia Patients With Prior CNS Involvement Undergoing Umbilical Cord Blood Transplantation 

Blood Science Update|A Prognostic Analysis of Acute Leukemia Patients With Prior CNS Involvement Undergoing Umbilical Cord Blood Transplantation 

Published in Blood Science in 2025, the study led by Zichang Shen examines the impact of central nervous system leukemia (CNSL) on outcomes after umbilical cord blood transplantation (UCBT). CNSL remains a difficult manifestation of acute leukemia because leukemic cells within the CNS can evade systemic chemotherapy and drive relapse. Although allogeneic transplantation is the most effective curative approach for high-risk disease, the influence of prior CNS involvement on post-transplant outcomes has remained uncertain. Shen and colleagues therefore evaluated how a history of CNSL affects long-term prognosis following UCBT. 
Blood Science Update|Alpha-Enolase Drives AML Progression via MAPK/ERK Signaling: Condensed Summary 

Blood Science Update|Alpha-Enolase Drives AML Progression via MAPK/ERK Signaling: Condensed Summary 

The commentary “Alpha-enolase promotes progression of acute myeloid leukemia via MAPK/ERK signaling pathway” by Zhang et al., published in Blood Science (2025), examines the clinical and biological significance of ENO1 in acute myeloid leukemia (AML). ENO1, a glycolytic enzyme with additional regulatory roles, has been implicated in several solid tumors, but its function in AML had not been fully clarified. Through integrated analyses of patient samples, functional assays, transcriptomics, and in vivo models, the authors demonstrate that ENO1 is overexpressed in AML and promotes disease progression mainly through MAPK/ERK pathway activation. 
 Comparing transplantation outcomes: haploidentical vs. unrelated donors 

 Comparing transplantation outcomes: haploidentical vs. unrelated donors 

At the 50th Annual Meeting of the EBMT in Glasgow, Scotland, Raynier Devillier, MD, PhD, of the Paoli-Calmettes Institute in Marseille, France, offered a detailed comparison of transplantation outcomes for patients receiving grafts from haploidentical versus unrelated donors. Dr. Devillier highlighted new data from The French Society of Marrow Transplantation and Cellular Therapy (SFGM-TC) that indicates survival outcomes are comparable between the two donor types. This finding allows clinicians greater flexibility to select a donor based on the individual needs of the patient. 
A New Era for AML Treatment: Integrating Novel Therapies and Global Collaboration 

A New Era for AML Treatment: Integrating Novel Therapies and Global Collaboration 

Professor Norbert Claude Gorin, the first Chair of the Global Committee of the European Society for Blood and Marrow Transplantation (EBMT), discussed the evolution of transplantation strategies for Acute Myeloid Leukemia (AML) and the importance of international cooperation. In an interview with Hematology Frontier during the second 2025 CTI conference in Hangzhou, he highlighted how decades of progress have reshaped the treatment landscape.